Please provide your email address to receive an email when new articles are posted on . The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in ...

Outcomes of concurrent chemo-radiotherapy (CCRT) in locally advanced cervical cancer (LACC). Results of a retrospective analysis of a single institution No significant financial relationships to ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...

Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Credit: GSK Dostarlimab plus carboplatin-paclitaxel reduced the risk of disease progression by 71% vs chemotherapy alone. The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in ...

The buzz created by two phase III studies testing immunotherapy in advanced or recurrent endometrial cancer at the Society of Gynecologic Oncology (SGO) annual meeting in April carried over to the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kevin Kalinsky, MD ...

Researchers at Baylor College of Medicine and the Broad Institute of MIT and Harvard and clinicians at Washington University in St. Louis have identified biological markers in triple negative breast ...

Mairéad McInerney will never know if changes in her treatment plan have undercut her odds of surviving stage 3 triple-negative breast cancer. Critical shortages in cancer drugs have forced her to ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...